Expression, regulation and function of intestinal drug transporters: an update
暂无分享,去创建一个
Stefan Oswald | S. Oswald | M. Droździk | Markus Keiser | Janett Müller | Janett Müller | M. Keiser | Marek Drozdzik
[1] C. Beglinger,et al. MAPPING OF MULTIDRUG RESISTANCE GENE 1 AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN ISOFORM 1 TO 5 mRNA EXPRESSION ALONG THE HUMAN INTESTINAL TRACT , 2005, Drug Metabolism and Disposition.
[2] Werner Weitschies,et al. Disposition and sterol‐lowering effect of ezetimibe are influenced by single‐dose coadministration of rifampin, an inhibitor of multidrug transport proteins , 2006, Clinical pharmacology and therapeutics.
[3] I. Gómez-Orellana. Strategies to improve oral drug bioavailability , 2005, Expert opinion on drug delivery.
[4] X. Chu,et al. Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development , 2014, Drug Metabolism and Disposition.
[5] Jeffrey C Stevens,et al. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[6] M. Pocard,et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. , 2010, Molecular pharmaceutics.
[7] Mary F Paine,et al. THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.
[8] T. Habuchi,et al. Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients , 2008, Therapeutic drug monitoring.
[9] T. Thalhammer,et al. Resveratrol and its major sulfated conjugates are substrates of organic anion transporting polypeptides (OATPs): impact on growth of ZR-75-1 breast cancer cells. , 2014, Molecular nutrition & food research.
[10] Takashi Baba,et al. Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. , 2012, Analytical chemistry.
[11] M. Miksits,et al. Sulfation of resveratrol in human liver: Evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1 , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[12] S. Härtter,et al. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. , 2013, British journal of clinical pharmacology.
[13] J. Nezu,et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. , 2000, Biochemical and biophysical research communications.
[14] Shobha Bhattachar,et al. The road map to oral bioavailability: an industrial perspective , 2006, Expert opinion on drug metabolism & toxicology.
[15] Y. Sugiyama,et al. Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.
[16] C. Gröer,et al. Mass Spectrometry-Based Targeted Proteomics as a Tool to Elucidate the Expression and Function of Intestinal Drug Transporters , 2013, The AAPS Journal.
[17] X. Jia,et al. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. , 2005, Current drug metabolism.
[18] Sheila Annie Peters,et al. Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models , 2016, Clinical Pharmacokinetics.
[19] H. Kroemer,et al. Intestinal expression of P‐glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate–glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans , 2006, Clinical pharmacology and therapeutics.
[20] Leslie Z. Benet,et al. The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.
[21] M. Nauck,et al. Compartment‐Specific Gene Regulation of the CAR Inducer Efavirenz In Vivo , 2012, Clinical pharmacology and therapeutics.
[22] M. Okuda,et al. MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: implication for intestinal barrier function. , 2014, Pharmacology & therapeutics.
[23] C. Klaassen,et al. Regulation of hepatic transporters by xenobiotic receptors. , 2005, Current drug metabolism.
[24] R. Neubert,et al. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). , 2005, Biochemical pharmacology.
[25] P. Borst,et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.
[26] Christer Tannergren,et al. Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[27] Bradley L Urquhart,et al. Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs , 2007, Journal of clinical pharmacology.
[28] T. Andersson,et al. Impact of OATP1B1, MDR1, and CYP3A4 Expression in Liver and Intestine on Interpatient Pharmacokinetic Variability of Atorvastatin in Obese Subjects , 2013, Clinical pharmacology and therapeutics.
[29] R. Kim,et al. Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans , 2007, Clinical pharmacology and therapeutics.
[30] Shuzhong Zhang,et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.
[31] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[32] Y Zhang,et al. The Gut as a Barrier to Drug Absorption , 2001, Clinical pharmacokinetics.
[33] D. Keppler,et al. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs , 2008, Expert opinion on drug metabolism & toxicology.
[34] B. Stieger,et al. Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene , 2012, Journal of Translational Medicine.
[35] Shigeki Sugiura,et al. ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS , 2005, Drug Metabolism and Disposition.
[36] M. Fromm,et al. Transporter‐Mediated Drug Uptake and Efflux: Important Determinants of Adverse Drug Reactions , 2011, Clinical pharmacology and therapeutics.
[37] Y. Lai,et al. Quantitative Targeted Proteomics for Membrane Transporter Proteins: Method and Application , 2014, The AAPS Journal.
[38] Michael D. Johnson,et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. , 2001, The Journal of pharmacology and experimental therapeutics.
[39] P. Neuvonen,et al. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.
[40] J. Mostertz,et al. Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study With Ezetimibe in Healthy Volunteers , 2012, Clinical pharmacology and therapeutics.
[41] X. Ming,et al. Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis. , 2016, Journal of pharmaceutical sciences.
[42] D. Keppler. The Roles of MRP2, MRP3, OATP1B1, and OATP1B3 in Conjugated Hyperbilirubinemia , 2014, Drug Metabolism and Disposition.
[43] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[44] P. Artursson,et al. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. , 1990, Journal of pharmaceutical sciences.
[45] A. Kong,et al. Induction of phase I, II and III drug metabolism/transport by xenobiotics , 2005, Archives of pharmacal research.
[46] M. H. Ensom,et al. Pharmacokinetic Effects of Bariatric Surgery , 2012, The Annals of pharmacotherapy.
[47] Erik Sjögren,et al. Direct In Vivo Human Intestinal Permeability (Peff ) Determined with Different Clinical Perfusion and Intubation Methods. , 2015, Journal of pharmaceutical sciences.
[48] D. Tibboel,et al. Human Intestinal PEPT1 Transporter Expression and Localization in Preterm and Term Infants , 2016, Drug Metabolism and Disposition.
[49] Li Di,et al. Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition. , 2014, Molecular pharmaceutics.
[50] E. Shin,et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer , 2007, Cancer.
[51] H. Schoemaker,et al. The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay. , 1993, British journal of clinical pharmacology.
[52] M. Coughtrie,et al. Absolute immunoquantification of the expression of ABC transporters P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein 2 in human liver and duodenum. , 2012, Biochemical pharmacology.
[53] M. Hediger,et al. Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. , 2013, Molecular aspects of medicine.
[54] I. Cascorbi,et al. MicroRNAs and their relevance to ABC transporters. , 2014, British journal of clinical pharmacology.
[55] T. Terasaki,et al. Large‐scale multiplex absolute protein quantification of drug‐metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH‐MS: Comparison with MRM/SRM and HR‐MRM/PRM , 2016, Proteomics.
[56] Curtis D. Klaassen,et al. Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation , 2010, Pharmacological Reviews.
[57] Michael Zschiesche,et al. Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction , 2000, Clinical pharmacology and therapeutics.
[58] W. Kramer. Transporters, Trojan horses and therapeutics: suitability of bile acid and peptide transporters for drug delivery , 2011, Biological chemistry.
[59] S. Cole,et al. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.
[60] B. Hirst,et al. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[61] Leslie Z Benet,et al. Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems , 2006, Journal of Pharmacology and Experimental Therapeutics.
[62] W. H. Barr,et al. Differential absorption of amoxicillin from the human small and large intestine , 1994, Clinical pharmacology and therapeutics.
[63] Christopher J Endres,et al. The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[64] S. Oswald,et al. Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. , 2015, Molecular pharmaceutics.
[65] Li Di,et al. Development of a new permeability assay using low-efflux MDCKII cells. , 2011, Journal of pharmaceutical sciences.
[66] R. Kim,et al. Nuclear receptors and drug disposition gene regulation. , 2005, Journal of pharmaceutical sciences.
[67] A. Mitra,et al. Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines. , 2013, International journal of pharmaceutics.
[68] J. Nezu,et al. Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in pH-Dependent Transport across Intestinal Apical Membrane , 2003, Journal of Pharmacology and Experimental Therapeutics.
[69] L Landmann,et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. , 2001, Gastroenterology.
[70] Huijun Sun,et al. Construction, identification and application of HeLa cells stably transfected with human PEPT1 and PEPT2 , 2012, Peptides.
[71] Wilhelm Kirch,et al. Grapefruit Juice Ingestion Significantly Reduces Talinolol Bioavailability , 2005, Clinical pharmacology and therapeutics.
[72] C. Beglinger,et al. Breast Cancer Resistance Protein and P-Glycoprotein Expression in Patients with Newly Diagnosed and Therapy-Refractory Ulcerative Colitis Compared with Healthy Controls , 2008, Digestion.
[73] Leslie Z Benet,et al. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. , 2008, Advanced drug delivery reviews.
[74] M. Fromm,et al. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[75] J. Wiśniewski,et al. The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition. , 2016, Journal of pharmaceutical sciences.
[76] M. Hediger,et al. The ABCs of membrane transporters in health and disease (SLC series): Introduction , 2013, Molecular aspects of medicine.
[77] Michael Zschiesche,et al. The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen , 2005, Pharmaceutical Research.
[78] M. Eichelbaum,et al. A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression , 2005, Biological chemistry.
[79] J. Unadkat,et al. Optimized Approaches for Quantification of Drug Transporters in Tissues and Cells by MRM Proteomics , 2014, The AAPS Journal.
[80] M. Fromm,et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. , 2000, The American journal of pathology.
[81] G. Kullak-Ublick,et al. Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. , 2012, Translational research : the journal of laboratory and clinical medicine.
[82] Oliver Burk,et al. Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin* , 2001, The Journal of Biological Chemistry.
[83] Jackie C Bloomer,et al. Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT “Pie” , 2009, Drug Metabolism and Disposition.
[84] P. Artursson,et al. PREDOMINANT CONTRIBUTION OF ORGANIC ANION TRANSPORTING POLYPEPTIDE OATP-B (OATP2B1) TO APICAL UPTAKE OF ESTRONE-3-SULFATE BY HUMAN INTESTINAL CACO-2 CELLS , 2006, Drug Metabolism and Disposition.
[85] H. Lennernäs. Clinical Pharmacokinetics of Atorvastatin , 2003, Clinical pharmacokinetics.
[86] J. Beijnen,et al. Multidrug Resistance Proteins 2 and 3 Provide Alternative Routes for Hepatic Excretion of Morphine-Glucuronides , 2007, Molecular Pharmacology.
[87] P. Artursson,et al. Efflux transporters in ulcerative colitis: Decreased expression of BCRP (ABCG2) and Pgp (ABCB1) , 2007, Inflammatory bowel diseases.
[88] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[89] X. Ming,et al. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. , 2011, Molecular pharmaceutics.
[90] H. Kroemer,et al. Disposition and Sterol-Lowering Effect of Ezetimibe in Multidrug Resistance-Associated Protein 2-Deficient Rats , 2006, Journal of Pharmacology and Experimental Therapeutics.
[91] C. Paulusma,et al. Oral Availability of Cefadroxil Depends on ABCC3 and ABCC4 , 2012, Drug Metabolism and Disposition.
[92] P. Dawson,et al. Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.
[93] X. Chu,et al. Interspecies Variability in Expression of Hepatobiliary Transporters across Human, Dog, Monkey, and Rat as Determined by Quantitative Proteomics , 2015, Drug Metabolism and Disposition.
[94] P. Artursson,et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[95] I. Tamai,et al. Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. , 2011, Journal of pharmaceutical sciences.
[96] S. Vavricka,et al. Regional Distribution of Solute Carrier mRNA Expression Along the Human Intestinal Tract , 2007, Drug Metabolism and Disposition.
[97] Fabian Müller,et al. Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects , 2013, Pharmacological Reviews.
[98] C. Beglinger,et al. Changes in mRNA Expression Levels of Solute Carrier Transporters in Inflammatory Bowel Disease Patients , 2009, Drug Metabolism and Disposition.
[99] L Zhang,et al. Emerging Transporters of Clinical Importance: An Update From the International Transporter Consortium , 2013, Clinical pharmacology and therapeutics.
[100] D. Rosskopf,et al. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1 , 2008, Pharmacogenetics and genomics.
[101] A Rostami-Hodjegan,et al. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. , 2013, Biopharmaceutics & drug disposition.
[102] J. Staudinger,et al. Nuclear-receptor–mediated regulation of drug– and bile-acid–transporter proteins in gut and liver , 2013, Drug metabolism reviews.
[103] A. Schinkel,et al. Complex Pharmacokinetic Behavior of Ezetimibe Depends on Abcc2, Abcc3, and Abcg2 , 2009, Drug Metabolism and Disposition.
[104] W. Sadee,et al. Intra- and Interindividual Variabilities of Valacyclovir Oral Bioavailability and Effect of Coadministration of an hPEPT1 Inhibitor , 2003, Antimicrobial Agents and Chemotherapy.
[105] L. Trahms,et al. Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[106] Gerd Mikus,et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. , 2003, British journal of clinical pharmacology.
[107] I. Kapetanovic,et al. Glucuronidation of trans‐resveratrol by human liver and intestinal microsomes and UGT isoforms , 2006, The Journal of pharmacy and pharmacology.
[108] Olivier Fardel,et al. Differential Regulation of Sinusoidal and Canalicular Hepatic Drug Transporter Expression by Xenobiotics Activating Drug-Sensing Receptors in Primary Human Hepatocytes , 2006, Drug Metabolism and Disposition.
[109] H. Colom,et al. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. , 2012, Archives of biochemistry and biophysics.
[110] T. Abe,et al. Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.
[111] S. Misaka,et al. Green Tea Ingestion Greatly Reduces Plasma Concentrations of Nadolol in Healthy Subjects , 2014, Clinical pharmacology and therapeutics.
[112] Paul D. Martin,et al. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure , 2016, Drug Metabolism and Disposition.
[113] Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects , 2012, European Journal of Clinical Pharmacology.
[114] Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases , 2015, Pharmaceutical Research.
[115] D. Keppler,et al. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.
[116] Leslie Z Benet,et al. Intestinal drug transporters: an overview. , 2013, Advanced drug delivery reviews.
[117] A. Ungell,et al. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[118] J. Brockmöller,et al. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. , 2013, Biochemical pharmacology.
[119] P. Artursson,et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[120] Li Di,et al. Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.
[121] J. Verschoor,et al. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. , 1987, Arzneimittel-Forschung.
[122] D. Bailey. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. , 2010, British journal of clinical pharmacology.
[123] G. Fricker,et al. Establishment of optimized MDCK cell lines for reliable efflux transport studies. , 2014, Journal of pharmaceutical sciences.
[124] Per Artursson,et al. Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.
[125] W. Kirch,et al. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. , 2000, International journal of clinical pharmacology and therapeutics.
[126] D. Lütjohann,et al. Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats. , 2010, Journal of pharmaceutical sciences.
[127] T. Nakanishi,et al. OATP transporter-mediated drug absorption and interaction. , 2013, Current opinion in pharmacology.
[128] M. Paine,et al. P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine , 2003, Pharmaceutical Research.
[129] Bruno Stieger,et al. Organic anion-transporting polypeptides. , 2014, Current topics in membranes.
[130] P. Dawson. Role of the intestinal bile acid transporters in bile acid and drug disposition. , 2011, Handbook of experimental pharmacology.
[131] Wolfgang Löscher,et al. Differences in the expression of endogenous efflux transporters in MDR1‐transfected versus wildtype cell lines affect P‐glycoprotein mediated drug transport , 2010, British journal of pharmacology.
[132] W. Kirch,et al. Direct demonstration of small intestinal secretion and site‐dependent absorption of the β‐blocker talinolol in humans , 1996, Clinical pharmacology and therapeutics.
[133] A. Rostami-Hodjegan,et al. Caco‐2 cells – expression, regulation and function of drug transporters compared with human jejunal tissue , 2017, Biopharmaceutics & drug disposition.
[134] H. Eichler,et al. Comparative Target Site Pharmacokinetics of Immediate‐ and Modified‐Release Formulations of Cefaclor in Humans , 2002, Journal of clinical pharmacology.
[135] H. Lennernäs,et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. , 2007, Molecular pharmaceutics.
[136] K. Maeda,et al. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP , 2012, British journal of pharmacology.
[137] A. Reichel,et al. Characterization of Cytochrome P450 Protein Expression along the Entire Length of the Intestine of Male and Female Rats , 2008, Drug Metabolism and Disposition.
[138] P. Langguth,et al. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[139] T. Baillie,et al. Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.
[140] P. Artursson,et al. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers , 2007, Nature Protocols.
[141] N. Hosten,et al. Characterization of the Intestinal and Hepatic Uptake/Efflux Transport of the Magnetic Resonance Imaging Contrast Agent Gadolinium-Ethoxylbenzyl-Diethylenetriamine-Pentaacetic Acid , 2014, Investigative radiology.
[142] K. Brouwer,et al. Organic Cation Transporter 1 (OCT1/mOct1) Is Localized in the Apical Membrane of Caco-2 Cell Monolayers and Enterocytes , 2013, Molecular Pharmacology.
[143] G. Ecker,et al. Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. , 2012, Drug discovery today.
[144] Kazuya Maeda,et al. Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.
[145] T. Nakanishi,et al. Interaction of Drug or Food with Drug Transporters in Intestine and Liver. , 2015, Current drug metabolism.
[146] M. Ostrowski,et al. Protein abundance of clinically relevant multidrug transporters along the entire length of the human intestine. , 2014, Molecular pharmaceutics.
[147] Maria Backlund,et al. Complete Knockout of Endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9. , 2016, Journal of pharmaceutical sciences.
[148] M. Brandsch. Drug transport via the intestinal peptide transporter PepT1. , 2013, Current opinion in pharmacology.
[149] H. Zimdahl,et al. International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms , 2013, Clinical pharmacology and therapeutics.
[150] K. Brouwer,et al. In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development , 2013, Clinical pharmacology and therapeutics.
[151] M. Eichelbaum,et al. Effects of rifampicin on global gene expression in human small intestine , 2007, Pharmacogenetics and genomics.
[152] I. Cascorbi,et al. Down-Regulation of ATP-Binding Cassette C2 Protein Expression in HepG2 Cells after Rifampicin Treatment Is Mediated by MicroRNA-379 , 2011, Molecular Pharmacology.
[153] S. Härtter,et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. , 2012, British journal of clinical pharmacology.